Default company panoramic image
Logo

Isomark, LLC

Isomark’s Canary™ early warning system uses patented breath monitoring technology to detect infections up to 2 days before standard methods.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Madison, WI, USA
  • Currency USD
  • Employees 3
  • Website isomark.com

Company Summary

Isomark developed a revolutionary technology that detects infections up to 2 days before standard methods. The initial target for Isomark is hospital-acquired infections (HAI) in the intensive care unit. Early detection of infections saves lives and money—it has been estimated HAIs cost the U.S. healthcare system more than $35 billion annually . Changes to the health care industry are driving hospitals to reduce costs and improve patient care.

Team

  • Default avatar
    Joe Kremer
    CEO
    Unconfirmed

    17-years of start-up experience including funding, creating and executing business strategy and building organizations. Most recently took a high tech firm from losses to net profit within 12 months.

  • Default avatar
    Dan Butz, PhD
    CSO
    Unconfirmed

    Assistant scientist in the UW-Madison Zoology Department focused on the early detection of diseases using metabolomic and isotopic approaches.

  • Default avatar
    Neil Holland
    Strategic Advisor
    Unconfirmed

    More than 25 years medical device industry management experience, including as Vice President of Global Device R&D at Hospira Inc.

  • Default avatar
    Mark Cook, PhD
    Board Chair and co-founder
    Unconfirmed

    Professor of Animal Sciences at UW-Madison with a scientific focus on the nutritional regulation of immune function.

  • Default avatar
    Ken Buroker
    FDA Consultant
    Unconfirmed

    More than 30 years experience in regulatory affairs and quality management, most recently led TomoTherapy through FDA approval and created the company’s quality control systems.

  • Default avatar
    Janice Hogan
    FDA Strategist
    Unconfirmed

    Co-Director of FDA/Medical Device practice at Hogan Lovells with twelve de novo petitions approved (15 percent of all FDA de novo petitions approved) and extensive connections with the FDA.

  • Default avatar
    Dr. Bruce Harms
    Medical Advisor
    Unconfirmed

    Former chief of the University of Wisconsin Hospital’s Section of Trauma and Surgical Critical Care.

  • Default avatar
    Dr. Doug Coursin
    Medical Advisor
    Unconfirmed

    Professor of Anesthesiology and Internal Medicine and is the Associate Director of the University of Wisconsin Hospital’s Trauma and Life Support Center.

Advisors

  • Default avatar
    Smith & Gesteland, LLP
    Accountant
    Unconfirmed